What is Inductive Bio?
Inductive Bio is a technology firm focused on revolutionizing therapeutic development through its advanced machine learning (ML) platform. The company's core innovation lies in its ability to dramatically accelerate compound optimization, a crucial and often protracted phase in creating new medicines. By constructing comprehensive datasets and employing state-of-the-art ML models, Inductive Bio maps the intricate drivers of small molecule Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET). This sophisticated approach empowers scientists to refine initial compounds into viable leads and development candidates with greater speed and an improved balance of ADMET properties, positioning Inductive Bio as a key player in the biopharmaceutical innovation landscape.
How much funding has Inductive Bio raised?
Inductive Bio has raised a total of $29.3M across 2 funding rounds:
Angel/Seed
$4.3M
Series A
$25M
Angel/Seed (2023): $4.3M with participation from Lux Capital, Andreessen Horowitz, AlleyCorp companies, and Bessemer Venture Partners
Series A (2025): $25M led by Lux Capital, S32, Amino Collective, Andreessen Horowitz, Obvious Ventures, and The Character Group
Key Investors in Inductive Bio
Lux Capital
Lux Capital is a European-Canadian multi-family office that connects enterprises to critical expertise, networks, and capital sources, focusing on financial securities, real estate, energy, and social impact investments. They empower innovation and sustainable growth through strategic investments.
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies, headquartered in Menlo Park, California.
Amino Collective
Amino Collective focuses on investing in health and bio sectors, supporting early-stage ventures with a European focus that aim to scale globally. They are dedicated to backing, connecting, and advancing entrepreneurs and scientists with innovative ideas.
What's next for Inductive Bio?
The substantial enterprise-level funding secured by Inductive Bio signals a pivotal growth phase, likely enabling the company to scale its operations, expand its research and development initiatives, and further enhance its ML platform's capabilities. This strategic investment is expected to accelerate the company's mission to bring novel therapeutics to market more efficiently. Future endeavors will likely focus on broadening its dataset, refining its predictive models, and forging strategic partnerships within the pharmaceutical and biotechnology sectors to leverage its technology across a wider range of therapeutic areas. The company's trajectory suggests a strong focus on market penetration and establishing its platform as an industry standard for drug discovery and optimization.
See full Inductive Bio company page
